Overall rank by patents
#27,960
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
The verdict
Abclon holds 9 US patents across 5 technology areas, rank #27,960 of 50,000 tracked assignees.
Abclon Inc. has been granted 9 US utility patents between 2019 and 2025, placing Abclon Inc. at rank #27,960 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.6 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Abclon Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Abclon sits between AB Medica S.p.a. (9 patents, rank #27,956) and Accurate Medical Therapeutics Ltd. (9 patents, rank #27,964) - the closest US assignees by grant volume. The composite Innovation Score of 35.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 2 in the 2015–2019 window, a +250% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Abclon Inc.'s 13.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Abclon Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
AB MEDICA S.P.A.
9 patents
ABAXX TECHNOLOGIES CORP.
9 patents
ABB Turbo Systems AG
9 patents
ABBISKO THERAPEUTICS CO., LTD.
9 patents
ABM Italia S.P.A.
9 patents
AC AVALANCHE, LLC
9 patents
ACANDIS GMBH & CO. KG
9 patents
ACCURATE MEDICAL THERAPEUTICS LTD.
9 patents
ABCLON INC.
9 patents
What this shows Abclon holds 9 patents at rank #27,960, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #27,960 in granted patent volume.
Other assignees with the most granted patents in Abclon's primary technology class.
Abclon's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
35 Top 50% higher than 50% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 2 | 22.2% |
| 2020 | 1 | 11.1% |
| 2022 | 2 | 22.2% |
| 2023 | 1 | 11.1% |
| 2024 | 2 | 22.2% |
| 2025 | 1 | 11.1% |
Top 5 of 5 technology areas
Overall rank by patents
#27,960
Across all tracked assignees
35.1 out of 100
How to use this portfolio
Abclon's 9 grants land it in the top 50% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.